41
Genovate Biotechnology Co., Ltd.
4130.TWO · TWO
$26.70 +0.00% (+$0.00)
Market Cap $3.14B
P/E Ratio -
Div. Yield -
ROE 0.60%
Bulios Fair Price
$18.34
31.3% downside
Current Price
$26.7
Undervalued Fair Value Overvalued
According to Bulios Fair Price, 4130.TWO is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
26 /100
Expensive P/B 1.57x
EV/EBITDA 105.46x
P/S 6.65x
Growth
36 /100
Stable Book val. growth 0.73%
Rev. growth 3.92%
FCF growth N/A
Profitability
13 /100
Weak Op. margin 3.65%
Gross margin 34.43%
FCF margin 9.47%
Quality
4 /100
Poor ROA 0.44%
ROIC 0.78%
Asset turnover 0.22x
Debt
80 /100
Low Int. coverage -18.75x
Debt/Equity 0.00x
Net debt/EBITDA -13.29x
Stability
31 /100
Unstable EPS volatility 215.75%
Beta 0.08x
Profitable years 3
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about 4130.TWO
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Chia-Chen Chu
Employees
193
Headquarters
Hsinchu City